BridgeMD
New treatment option for Spinocerebellar Ataxia
Official title Ophthalmological Disorders in Dominant Spinal-cerebellar Ataxias
ClinicalTrials.gov ID: NCT07019558
What this study is testing
- What it's testing
- Spinocerebellar ataxias (SCA) are rare genetic neurological disorders. The most common forms are SCA1, SCA2 and SCA3.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Age between 18 and 80,
- Presence of pathological expansion in ATXN1 (\> or equal to 39 CAG), ATXN2 (\> or equal to 33 CAG) or ATXN3 (\> or equal to 45 CAG) genes...
- Sujet symptomatic (SARA greater than or equal to 4) or presymptomatic (SARA \< 4).
You likely can't join if
- Study-specific criteria:
- people with systemic or ophthalmological disease that could affect the retina, impair fundus examination (severe cataract, severe/decompensated...
- people with extremely severe neurological impairment, with a significant impact on the ability to perform most ophthalmological examinations; for...
- General exclusion criteria relating to regulations:
- Failure to obtain consent (adults, non-emancipated minors, persons not in a position to give consent, research carried out in emergency situations...
- Participants who have reached the maximum amount of compensation for their participation inresearch,
See the full eligibility criteria
- Age between 18 and 80,
- Presence of pathological expansion in ATXN1 (\> or equal to 39 CAG), ATXN2 (\> or equal to 33 CAG) or ATXN3 (\> or equal to 45 CAG) genes, responsible respectively for SCA1, SCA2 or SCA3 or a pathological expansion...
- Sujet symptomatic (SARA greater than or equal to 4) or presymptomatic (SARA \< 4).
- Study-specific criteria:
- people with systemic or ophthalmological disease that could affect the retina, impair fundus examination (severe cataract, severe/decompensated diabetes), or cause visual acuity below 20/40, intraocular pressure \> 20...
- people with extremely severe neurological impairment, with a significant impact on the ability to perform most ophthalmological examinations; for example in patients for whom sitting, even with back support and cannot...
- General exclusion criteria relating to regulations:
- Failure to obtain consent (adults, non-emancipated minors, persons not in a position to give consent, research carried out in emergency situations, etc.),
- Participants who have reached the maximum amount of compensation for their participation inresearch,
- Non-affiliation with a social security scheme,
- Persons placed under court protection,
- Person taking part in research.
The study team makes the final eligibility decision.
Where it's taking place
- Montpellier, Hérault, France
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Montpellier, Hérault, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.